These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 2640049)

  • 1. [Evaluation of the effectiveness and tolerability of gliquidone in the treatment of diabetes mellitus type II].
    Iori I; Bosi E; Manicardi E; Del Din G; Dini FL; Portioli I
    Riv Eur Sci Med Farmacol; 1989 Jun; 11(3):277-83. PubMed ID: 2640049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy.
    Habib SS; Aslam M; Naveed AK; Razi MS
    Saudi Med J; 2006 Feb; 27(2):174-80. PubMed ID: 16501671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Multicenter study with gliquidone in type 2 diabetes mellitus].
    Kreze A; Vozár J; Rázus P; Lacko A; Málek Z; Putz Z
    Vnitr Lek; 1991; 37(9-10):761-7. PubMed ID: 1771808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combined therapy with insulin/gliquidone (Glurenorm) in type 2 diabetes after treatment failure using oral antidiabetic agents].
    Podrouzková B; Krusová D
    Vnitr Lek; 1992 Oct; 38(10):963-7. PubMed ID: 1481374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of gliquidone in Thai diabetics.
    Nitiyanant W; Sriussadaporn S; Deerochanawong C; Ngawngamrat S; Benjasuratwong Y; Patanaungkul S
    J Med Assoc Thai; 1997 Dec; 80(12):771-7. PubMed ID: 9470330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on the mechanism of action of sulphonylureas in type II diabetic subjects: gliquidone.
    Bonora E; Moghetti P; Querena M; Zenere M; Cacciatori V; Tosi F; Travia D; Zoppini G; Muggeo M
    J Endocrinol Invest; 1992 Jan; 15(1):1-11. PubMed ID: 1560186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study.
    Aravind SR; Al Tayeb K; Ismail SB; Shehadeh N; Kaddaha G; Liu R; Balshaw R; Lesnikova N; Heisel O; Girman CJ; Musser BJ; Davies MJ; Katzeff HL; Engel SS; Radican L;
    Curr Med Res Opin; 2011 Jun; 27(6):1237-42. PubMed ID: 21506631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible risk of sulphonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease.
    Fasching P
    Diabetologia; 1998 Jun; 41(6):743-4. PubMed ID: 9662063
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful treatment of markedly symptomatic patients with type II diabetes mellitus using high doses of sulfonylurea agents.
    Davidson MB
    West J Med; 1992 Aug; 157(2):199-200. PubMed ID: 1441492
    [No Abstract]   [Full Text] [Related]  

  • 12. [The use of the hypoglycemic preparation gliquidone in patients with digestive organ diseases combined with diabetes mellitus].
    Degtiareva II; Lodianaia EV; Opanasiuk ND; Palladina OL
    Lik Sprava; 1995; (7-8):84-7. PubMed ID: 8846383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gliquidone contributes to improvement of type 2 diabetes mellitus management: a review of pharmacokinetic and clinical trial data.
    Malaisse WJ
    Drugs R D; 2006; 7(6):331-7. PubMed ID: 17073516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetic control with gliquidone--a short acting sulphonylurea.
    Borthwick LJ; Wilson S
    Eur J Clin Pharmacol; 1984; 26(4):475-9. PubMed ID: 6428917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hyperplastic skin reactions as the side effects of sulfonylurea preparations (the clinical manifestations and diagnosis)].
    Potekaev NS; Kurdina MI
    Ter Arkh; 1992; 64(10):24-6. PubMed ID: 1485245
    [No Abstract]   [Full Text] [Related]  

  • 16. [Does hypoglycemic treatment with gliclazide and gliquidone affect platelet function in type II diabetic patients?].
    Strojek K; Bresler M; Gumprecht J; Grzeszczak W; Trautsolt W
    Pol Arch Med Wewn; 1993 Apr; 89(4):315-9. PubMed ID: 8351232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse drug reaction: a possible case of glimepiride-induced syndrome of inappropriate antidiuretic hormone secretion.
    Adachi H; Yanai H
    Diabetes Metab; 2015 Apr; 41(2):176-7. PubMed ID: 25559655
    [No Abstract]   [Full Text] [Related]  

  • 18. Sulphonylurea dose-response relationships: relation to clinical practice.
    Lindblad U; Melander A
    Diabetes Obes Metab; 2000 Jan; 2(1):25-31. PubMed ID: 11220350
    [No Abstract]   [Full Text] [Related]  

  • 19. Sulfonylurea treatment in type 2 diabetes.
    Bester K; Ton J; Korownyk C
    Can Fam Physician; 2018 Apr; 64(4):295. PubMed ID: 29650607
    [No Abstract]   [Full Text] [Related]  

  • 20. The second-generation sulfonylureas: change or progress?
    Kreisberg RA
    Ann Intern Med; 1985 Jan; 102(1):125-6. PubMed ID: 3966729
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.